An interventional study of Ab-interno canaloplasty utilizing the iTrack Advance device and Ab-interno canaloplasty utilizing the OMNI Surgical System in Primary Open Angle Glaucoma, sponsored by Nova Eye, Inc.. Recruiting at 5 sites in 3 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-04-18.
Sponsored by Nova Eye, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Glaucoma, Open-Angle with a site in United Kingdom — 5 open to participants now, 7 under way, 1 of them phase 3. Glaucoma, Open-Angle · United Kingdom.
Among the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 32nd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →5 of the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom are open now. Recruiting first, the newest first:
Santen SAS · Sites in United Kingdom, Austria, Belgium and 5 more countries
Ages 18–85
University College, London · Sites in United Kingdom
Ages 18+
Elios Vision, Inc. · Sites in United Kingdom, Belgium, France and 3 more countries
Ages 40+
iSTAR Medical · Sites in United Kingdom, Panama, Spain
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 1992; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 86 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 229 across the 26 interventional studies, 205 across the 8 observational. Of the 26 that completed or were terminated, 10 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 34 have an industry lead sponsor. The 10 most frequent:
Nova Eye, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Nova Eye, Inc. has 3 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma, Open-Angle with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05405868Phase 3University College, LondonNicotinamide in Glaucoma (NAMinG): A Randomised, Placebo-controlled, Multi-centre, Phase III Trial | 2027-04-30 |
| NCT05786196Nova Eye, Inc.Multicenter Glaucoma Study Investigating Standalone Canaloplasty | 2026-12 |
| NCT05024695iSTAR MedicalEvaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma. | 2027-07 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Glaucoma, Open-Angle with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrack™ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following prior treatments for glaucoma (study eye):
Laser trabeculoplasty
i. Selective Laser Trabeculoplasty (SLT) conducted within 6-months of the Screening Visit ii. Prior Argon Laser Trabeculoplasty
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ab-interno canaloplasty utilizing the iTrack Advance microcatheter device (Nova Eye, Inc.)
Device: Ab-interno canaloplasty utilizing the iTrack Advance device
Ab-interno canaloplasty utilizing the OMNI Surgical System
Device: Ab-interno canaloplasty utilizing the OMNI Surgical System
360 degree microcatheterization and viscodilation of Schlemm's canal
360 degree microcatheterization and viscodilation of Schlemm's canal
The mean change in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline
IOP will be measured at each visit with Goldmann applanation tonometry
Time frame: 12 months
Percentage of eyes achieving a 20% or greater reduction in unmedicated Intraocular pressure (IOP) at Month-12 compared to baseline and without any other intervention (medication or secondary surgery)
IOP will be measured at each visit with Goldmann applanation tonometry
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 43 months is above that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nova Eye, Inc.